

Plasminogen

Cat. No.:	HY-P2821
CAS No.:	9001-91-6
Target:	Others
Pathway:	Others
Storage:	Sealed storage, away from moisture
	Powder -80°C 2 years
	-20°C 1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Plasminogen

BIOLOGICAL ACTIVITY

Description	<p>Plasminogen is a secreted protein that upon cleavage by urokinase plasminogen activator (uPA) or tissue plasminogen activator (tPA) is converted to plasmin, a broad range protease capable of cleaving fibrin and other ECM components. Plasminogen also is a proinflammatory regulator that accelerates the healing of acute and diabetic wounds. Plasminogen can be used in studies of wound healing, inflammation and hypoplasminogenemia^{[1][2]}.</p>												
In Vivo	<p>Plasminogen (plg) (2 mg/per; i.v.; single daily for 16 days) accelerates the healing of burn wounds in WT mice^[1]. Plasminogen (plg) (2 mg/per; i.v.; single daily for 16 days) enhances the expression of IL-6 and augments the activation of STAT3 in wounded skin of both WT and plg-deficient mice^[1]. Plasminogen (plg) (2 mg/per; i.v.; single daily for 24 days) improves the healing of burn wounds in a mouse model of diabetes^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>WT mice (plg-heterozygous (plg^{+/-})) mice, plg^{+/-} and plg-deficient (plg^{-/-}) mice (C57BL/6 background; 8- to 10- week-old; burn-wound model)^[1].</td> </tr> <tr> <td>Dosage:</td> <td>2 mg/per</td> </tr> <tr> <td>Administration:</td> <td>Intravenous injection; single daily for 16 days.</td> </tr> <tr> <td>Result:</td> <td> <p>Showed a significantly faster healing speed than control group at day 6, and the time to healing (ie, the scab falling off) was also approximately 2 days earlier than in the control group.</p> <p>Promoted epithelium layer fused to reepithelialize the wound completely, and only a small scab remained lightly attached above the wound when at day 11.</p> <p>Enhanced the level of IL-6 in the wounds of both WT and plg-deficient mice, and increased the pSTA T3 level in the wound.</p> </td> </tr> <tr> <td>Animal Model:</td> <td>Genetically diabetic mice (C57BLKS db/db; at least 10 weeks old; with a minimal blood glucose level of 15 mM) and control heterozygous littermates (C57BLKS db/+; at least 10 weeks old; with a minimal blood glucose level of 7.8 mM)^[1].</td> </tr> <tr> <td>Dosage:</td> <td>2 mg/per</td> </tr> </table>	Animal Model:	WT mice (plg-heterozygous (plg ^{+/-})) mice, plg ^{+/-} and plg-deficient (plg ^{-/-}) mice (C57BL/6 background; 8- to 10- week-old; burn-wound model) ^[1] .	Dosage:	2 mg/per	Administration:	Intravenous injection; single daily for 16 days.	Result:	<p>Showed a significantly faster healing speed than control group at day 6, and the time to healing (ie, the scab falling off) was also approximately 2 days earlier than in the control group.</p> <p>Promoted epithelium layer fused to reepithelialize the wound completely, and only a small scab remained lightly attached above the wound when at day 11.</p> <p>Enhanced the level of IL-6 in the wounds of both WT and plg-deficient mice, and increased the pSTA T3 level in the wound.</p>	Animal Model:	Genetically diabetic mice (C57BLKS db/db; at least 10 weeks old; with a minimal blood glucose level of 15 mM) and control heterozygous littermates (C57BLKS db/+; at least 10 weeks old; with a minimal blood glucose level of 7.8 mM) ^[1] .	Dosage:	2 mg/per
Animal Model:	WT mice (plg-heterozygous (plg ^{+/-})) mice, plg ^{+/-} and plg-deficient (plg ^{-/-}) mice (C57BL/6 background; 8- to 10- week-old; burn-wound model) ^[1] .												
Dosage:	2 mg/per												
Administration:	Intravenous injection; single daily for 16 days.												
Result:	<p>Showed a significantly faster healing speed than control group at day 6, and the time to healing (ie, the scab falling off) was also approximately 2 days earlier than in the control group.</p> <p>Promoted epithelium layer fused to reepithelialize the wound completely, and only a small scab remained lightly attached above the wound when at day 11.</p> <p>Enhanced the level of IL-6 in the wounds of both WT and plg-deficient mice, and increased the pSTA T3 level in the wound.</p>												
Animal Model:	Genetically diabetic mice (C57BLKS db/db; at least 10 weeks old; with a minimal blood glucose level of 15 mM) and control heterozygous littermates (C57BLKS db/+; at least 10 weeks old; with a minimal blood glucose level of 7.8 mM) ^[1] .												
Dosage:	2 mg/per												

Administration:	Intravenous injection; single daily for 24 days.
Result:	Shown time to healing (ie, the scab falling off) was significantly earlier (approximately 3 days) than the control group. Accelerated the injured epithelium layer and the underlying tissue healed. (the front of the epithelium layer in the control group had barely fused and was covered by a scab. In addition, the tissue underneath the scab was inflamed).

REFERENCES

- [1]. Shen Y, et al. Plasminogen is a key proinflammatory regulator that accelerates the healing of acute and diabetic wounds. *Blood*. 2012 Jun 14;119(24):5879-87.
- [2]. Keragala CB, et al. Plasminogen: an enigmatic zymogen. *Blood*. 2021 May 27;137(21):2881-2889.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA